NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrintยฎ in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrintยฎ in Breast Cancer Guidelines
Read MoreAgendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreAgendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrintยฎ + BluePrintยฎโs Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read MoreAgendiaยฎ Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michiganโs Dr. Erin Cobain
SWOG S2206 will use MammaPrintยฎ breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read MoreMammaPrintยฎ approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrintยฎ for inclusion in the Dutch National health insurance basic package with immediate effect.
Read More